Volume | 13,960 |
|
|||||
News | - | ||||||
Day High | 2.80 | Low High |
|||||
Day Low | 2.63 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
AYTU BioPharma Inc | AYTU | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.70 | 2.63 | 2.80 | 2.80 | 2.715 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
119 | 13,960 | $ 2.67 | $ 37,259 | - | 1.38 - 3.50 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:00:00 | 52 | $ 2.76 | USD |
AYTU BioPharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
14.7M | 5.57M | - | 107.4M | -17.05M | -3.06 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
AYTU BioPharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AYTU Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.94 | 2.94 | 2.63 | 2.78 | 6,048 | -0.14 | -4.76% |
1 Month | 3.06 | 3.38 | 2.63 | 3.02 | 16,651 | -0.26 | -8.50% |
3 Months | 2.85 | 3.45 | 2.48 | 3.01 | 21,791 | -0.05 | -1.75% |
6 Months | 2.93 | 3.45 | 2.20 | 2.79 | 28,750 | -0.13 | -4.44% |
1 Year | 2.61 | 3.50 | 1.38 | 2.45 | 74,572 | 0.19 | 7.28% |
3 Years | 136.20 | 144.00 | 1.38 | 30.32 | 492,495 | -133.40 | -97.94% |
5 Years | 39.20 | 235.286 | 1.38 | 34.87 | 2,178,204 | -36.40 | -92.86% |
AYTU BioPharma Description
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. |